Together, dual PI3K/MTOR inhibitors such as NVP-BGT226 or NVP-BEZ235 may be of special clinical value in the desperate case of tumor progress due to TKI-resistance, which is an ever increasing problem in the treatment of relapsed acute leukemia. This evidence concerns the gene MTOR and acute leukemia.